- Home
- MNOV vs AVTX Comparison
MNOV vs AVTX Comparison
Compare MNOV & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | AVTX |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9M | 328.4M |
| IPO Year | 2004 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MNOV | AVTX |
|---|---|---|
| Price | $1.39 | $14.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $7.50 | ★ $40.57 |
| AVG Volume (30 Days) | 25.0K | ★ 777.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | $2,360,807.00 | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $180.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 194.15 | ★ 2312.27 |
| 52 Week Low | $1.17 | $3.39 |
| 52 Week High | $1.96 | $20.72 |
Technical Indicators
Market Signals| Indicator | MNOV | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 48.22 |
| Support Level | $1.21 | $13.34 |
| Resistance Level | $1.43 | $15.63 |
| Average True Range (ATR) | 0.06 | 1.09 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 22.22 | 35.61 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.